223 related articles for article (PubMed ID: 29440146)
1. A DDX31/Mutant-p53/EGFR Axis Promotes Multistep Progression of Muscle-Invasive Bladder Cancer.
Daizumoto K; Yoshimaru T; Matsushita Y; Fukawa T; Uehara H; Ono M; Komatsu M; Kanayama HO; Katagiri T
Cancer Res; 2018 May; 78(9):2233-2247. PubMed ID: 29440146
[TBL] [Abstract][Full Text] [Related]
2. DDX31 regulates the p53-HDM2 pathway and rRNA gene transcription through its interaction with NPM1 in renal cell carcinomas.
Fukawa T; Ono M; Matsuo T; Uehara H; Miki T; Nakamura Y; Kanayama HO; Katagiri T
Cancer Res; 2012 Nov; 72(22):5867-77. PubMed ID: 23019224
[TBL] [Abstract][Full Text] [Related]
3. S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy.
Kim WT; Kim J; Yan C; Jeong P; Choi SY; Lee OJ; Chae YB; Yun SJ; Lee SC; Kim WJ
Ann Oncol; 2014 May; 25(5):974-9. PubMed ID: 24631944
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival.
Helal DS; Darwish SA; Awad RA; Ali DA; El-Guindy DM
Diagn Pathol; 2023 Feb; 18(1):11. PubMed ID: 36737799
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic Cancer Progression Relies upon Mutant p53-Induced Oncogenic Signaling Mediated by NOP14.
Du Y; Liu Z; You L; Hou P; Ren X; Jiao T; Zhao W; Li Z; Shu H; Liu C; Zhao Y
Cancer Res; 2017 May; 77(10):2661-2673. PubMed ID: 28280038
[TBL] [Abstract][Full Text] [Related]
6. Identification of prognostic biomarkers associated with stromal cell infiltration in muscle-invasive bladder cancer by bioinformatics analyses.
Li P; Cao J; Li J; Yao Z; Han D; Ying L; Wang Z; Tian J
Cancer Med; 2020 Oct; 9(19):7253-7267. PubMed ID: 32786144
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of long non-coding RNA TUG1 predicts poor prognosis and promotes cancer cell proliferation and migration in high-grade muscle-invasive bladder cancer.
Iliev R; Kleinova R; Juracek J; Dolezel J; Ozanova Z; Fedorko M; Pacik D; Svoboda M; Stanik M; Slaby O
Tumour Biol; 2016 Oct; 37(10):13385-13390. PubMed ID: 27460088
[TBL] [Abstract][Full Text] [Related]
8. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
[TBL] [Abstract][Full Text] [Related]
9. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.
Wallerand H; Cai Y; Wainberg ZA; Garraway I; Lascombe I; Nicolle G; Thiery JP; Bittard H; Radvanyi F; Reiter RR
Urol Oncol; 2010; 28(2):180-8. PubMed ID: 19070520
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of altered nm23-H1, EGFR, RB and p53 expression in bilharzial bladder cancer.
Khaled HM; Bahnassy AA; Raafat AA; Zekri AR; Madboul MS; Mokhtar NM
BMC Cancer; 2009 Jan; 9():32. PubMed ID: 19171060
[TBL] [Abstract][Full Text] [Related]
11. SH3BGRL3 Protein as a Potential Prognostic Biomarker for Urothelial Carcinoma: A Novel Binding Partner of Epidermal Growth Factor Receptor.
Chiang CY; Pan CC; Chang HY; Lai MD; Tzai TS; Tsai YS; Ling P; Liu HS; Lee BF; Cheng HL; Ho CL; Chen SH; Chow NH
Clin Cancer Res; 2015 Dec; 21(24):5601-11. PubMed ID: 26286913
[TBL] [Abstract][Full Text] [Related]
12. A TP53-based immune prognostic model for muscle-invasive bladder cancer.
Li H; Lu H; Cui W; Huang Y; Jin X
Aging (Albany NY); 2020 Dec; 13(2):1929-1946. PubMed ID: 33323544
[TBL] [Abstract][Full Text] [Related]
13. Mutant p53 induces EZH2 expression and promotes epithelial-mesenchymal transition by disrupting p68-Drosha complex assembly and attenuating miR-26a processing.
Jiang FZ; He YY; Wang HH; Zhang HL; Zhang J; Yan XF; Wang XJ; Che Q; Ke JQ; Chen Z; Tong H; Zhang YL; Wang FY; Li YR; Wan XP
Oncotarget; 2015 Dec; 6(42):44660-74. PubMed ID: 26587974
[TBL] [Abstract][Full Text] [Related]
14. B7‑H3 promotes malignant progression of muscle‑invasive bladder cancer.
Xu ZL; Zhang Y; Wang L; Li F; Man HW; Li PF; Shan BE
Oncol Rep; 2018 Nov; 40(5):2722-2733. PubMed ID: 30132557
[TBL] [Abstract][Full Text] [Related]
15. TPX2-p53-GLIPR1 regulatory circuitry in cell proliferation, invasion, and tumor growth of bladder cancer.
Yan L; Li Q; Yang J; Qiao B
J Cell Biochem; 2018 Feb; 119(2):1791-1803. PubMed ID: 28799673
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA expression profiles in muscle-invasive bladder cancer: identification of a four-microRNA signature associated with patient survival.
Xu Z; Yu YQ; Ge YZ; Zhu JG; Zhu M; Zhao YC; Xu LW; Yang XB; Geng LG; Dou QL; Jia RP
Tumour Biol; 2015 Sep; 36(10):8159-66. PubMed ID: 25990459
[TBL] [Abstract][Full Text] [Related]
17. Dynamic expression changes between non-muscle-invasive bladder cancer and muscle-invasive bladder cancer.
Zhao YG; Shi BY; Qian YY; Bai HW; Xiao L; He XY
Tumori; 2014; 100(6):e273-81. PubMed ID: 25688510
[TBL] [Abstract][Full Text] [Related]
18. High expression of MMP14 is associated with progression and poor short-term prognosis in muscle-invasive bladder cancer.
Wang JF; Gong YQ; He YH; Ying WW; Li XS; Zhou XF; Zhou LQ
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(12):6605-6615. PubMed ID: 32633349
[TBL] [Abstract][Full Text] [Related]
19. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
Seiler R; Oo HZ; Tortora D; Clausen TM; Wang CK; Kumar G; Pereira MA; Ørum-Madsen MS; Agerbæk MØ; Gustavsson T; Nordmaj MA; Rich JR; Lallous N; Fazli L; Lee SS; Douglas J; Todenhöfer T; Esfandnia S; Battsogt D; Babcook JS; Al-Nakouzi N; Crabb SJ; Moskalev I; Kiss B; Davicioni E; Thalmann GN; Rennie PS; Black PC; Salanti A; Daugaard M
Eur Urol; 2017 Jul; 72(1):142-150. PubMed ID: 28408175
[TBL] [Abstract][Full Text] [Related]
20. The Splicing Factor PTBP1 Promotes Expression of Oncogenic Splice Variants and Predicts Poor Prognosis in Patients with Non-muscle-Invasive Bladder Cancer.
Bielli P; Panzeri V; Lattanzio R; Mutascio S; Pieraccioli M; Volpe E; Pagliarulo V; Piantelli M; Giannantoni A; Di Stasi SM; Sette C
Clin Cancer Res; 2018 Nov; 24(21):5422-5432. PubMed ID: 30012566
[No Abstract] [Full Text] [Related]
[Next] [New Search]
